Targeting Mutated Plus Germline Epitopes Confers Pre-clinical Efficacy of an Instantly Formulated Cancer Nano-Vaccine
Personalized cancer vaccines hold promises for future cancer therapy. Targeting neoantigens is perceived as more beneficial compared to germline, non-mutated antigens. However, it is a practical challenge to identify and vaccinate patients with neoantigens. Here we asked whether two neoantigens are...
Main Authors: | Mona O. Mohsen, Monique Vogel, Carsten Riether, Julius Muller, Silvia Salatino, Nicola Ternette, Ariane C. Gomes, Gustavo Cabral-Miranda, Aadil El-Turabi, Christiane Ruedl, Thomas M. Kundig, Said Dermime, Alexander Knuth, Daniel E. Speiser, Martin F. Bachmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.01015/full |
Similar Items
-
Targeting mutated plus germline epitopes confers pre-clinical efficacy of an instantly formulated cancer nano-vaccine
by: Mohsen, M, et al.
Published: (2019) -
Increased receptor affinity of SARS-CoV-2: a new immune escape mechanism
by: Martin F. Bachmann, et al.
Published: (2022-05-01) -
SARS-CoV-2 structural features may explain limited neutralizing-antibody responses
by: Martin F. Bachmann, et al.
Published: (2021-01-01) -
Harnessing Nanoparticles for Immunomodulation and Vaccines
by: Ariane C. Gomes, et al.
Published: (2017-02-01) -
Vaccination using mutated receptor binding domains of SARS-CoV-2: Evidence for partial immune escape but not serotype formation
by: Xinyue Chang, et al.
Published: (2023-02-01)